Glycopyrronium tosylate | CAS# 1624259-25-1 | topical anticholinergic

MedKoo Cat#: 413926 | Name: Glycopyrronium tosylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Glycopyrronium tosylate is a topical anticholinergic developed for once-daily treatment of primary axillary hyperhidrosis.

Chemical Structure

Glycopyrronium tosylate

CAS#1624259-25-1

Theoretical Analysis

MedKoo Cat#: 413926

Name: Glycopyrronium tosylate

CAS#: 1624259-25-1

Chemical Formula: C26H37NO7S

Exact Mass: 507.2291

Molecular Weight: 507.64

Elemental Analysis: C, 61.52; H, 7.35; N, 2.76; O, 22.06; S, 6.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Glycopyrronium tosylate; DRM 04 tosylate; DRM-04 tosylate; DRM04 tosylate

IUPAC/Chemical Name

3-(2-Cyclopentyl(hydroxy)phenylacetoxy)-1,1-dimethylpyrrolidinium 4-methylbenzenesulfonate hydrate (1:1:1)

InChi Key

UOWOLENSDISMPG-UHFFFAOYSA-M

InChi Code

InChI=1S/C19H28NO3.C7H8O3S.H2O/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;1-6-2-4-7(5-3-6)11(8,9)10;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;2-5H,1H3,(H,8,9,10);1H2/q+1;;/p-1

SMILES Code

C[N+]1(C)CC(OC(C(O)(C2CCCC2)C3=CC=CC=C3)=O)CC1.O=S(C4=CC=C(C)C=C4)([O-])=O.[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 507.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis. Skin Therapy Lett. 2019 Mar;24(2):1-3. PMID: 30970203. 2: Lamb YN. Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use. Clin Drug Investig. 2019 Nov;39(11):1141-1147. doi: 10.1007/s40261-019-00853-x. Erratum in: Clin Drug Investig. 2020 Jan;40(1):103. PMID: 31571127; PMCID: PMC6877702. 3: Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, Quiring J, Drew J, Pariser DM. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. Am J Clin Dermatol. 2019 Aug;20(4):593-604. doi: 10.1007/s40257-019-00446-6. PMID: 31111409; PMCID: PMC6687675. 4: Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials. Am J Clin Dermatol. 2019 Feb;20(1):135-145. doi: 10.1007/s40257-018-0395-0. PMID: 30378087; PMCID: PMC6516143. 5: Caserta F, Lenn J, Hofland H. Variables Affecting Delivery of Glycopyrronium Tosylate Through Human Skin In Vitro. J Drugs Dermatol. 2020 Nov 1;19(11):1080-1085. doi: 10.36849/JDD.2020.5062. PMID: 33196749. 6: Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatr Dermatol. 2019 May;36(3):424. doi: 10.1111/pde.13877. Erratum for: Pediatr Dermatol. 2019 Jan;36(1):89-99. PMID: 31099927; PMCID: PMC6885915. 7: Bindernagel R, Kimmis BD, Liu D. Use of topical 2.4% glycopyrronium tosylate in familial benign pemphigus (Hailey-Hailey disease). Dermatol Online J. 2020 Oct 15;26(10):13030/qt01j7n9qw. PMID: 33147680. 8: Lamb YN. Correction to: Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use. Clin Drug Investig. 2020 Jan;40(1):103. doi: 10.1007/s40261-019-00878-2. Erratum for: Clin Drug Investig. 2019 Nov;39(11):1141-1147. PMID: 31782126; PMCID: PMC6962278. 9: Arnold MJ, O'Connor C. Glycopyrronium (Qbrexza) Topical Wipes for Hyperhidrosis. Am Fam Physician. 2019 Sep 15;100(6):372-373. PMID: 31524358. 10: Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok R, Drew J, Quiring J, Pariser DM. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019 Jan;80(1):128-138.e2. doi: 10.1016/j.jaad.2018.07.002. Epub 2018 Jul 10. PMID: 30003988.